3Adams HP.Emergent use of anticoagulation for treatment of patients with ischemic stroke[J].Stroke,2002,33:856 -861.
4Moonis M,Fisher M.Considering the role of heparin and low molecular weight heparins in acute ischemic stroke[J].Stroke,2002,33(7):1927-1933.
5Coull BM,Williams LS,Goldstein LB,et al.Joint Stroke Guideline.Development Committee of the American Academy of Neurology; American Stroke Association.Anticoagulants and antiplatelet agentsin acute ischemic stroke:report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association[J].Stroke,2002,33(7):1934-1942.
6Adams HP,Adams RJ,Brott T,et al.Stroke Council of the American Stroke Association.Guidelines for the early management of patients with ischemic stroke:A scientific statement from the Stroke Council of the American Stroke Association[J].Stroke,2003,34(4):1056-1083.
7The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.Low molecular weight heparinoid,ORG 10172 (danaparoid),and outcome after acute ischemic stroke:a randomized controlled trial[J].JAMA,1998,279:1265-1272.
8Berge E,Abdelnoor M,Nakstad PH,et al.On behalf of the Heparin in Acute Embolic Stroke Trial (HAEST) Study Group.Low molecula rweight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation:a double-blind randomised study[J].Lancet,2000,355:1205-1210.
